FDA Finalizes Pulmonary TB Drug Development Guidance for Antibacterial Sponsors in 2026

A finalized regulatory framework for pulmonary tuberculosis drug development is now in effect, giving antibacterial sponsors clearer clinical trial expectations from FDA's Center for Drug Evaluation and Research (CDER) as they advance candidates through IND and NDA stages. The guidance, titled Pulmonary Tuberculosis: Developing Drugs for Treatment, closes a drafting cycle that opened in December 2022 under docket FDA-2013-D-1319.

For regulatory affairs leads and clinical development teams, the finalization signals that CDER has reviewed and incorporated, or declined, industry comment submitted against the 2022 draft. Sponsors who submitted comments during the draft period should conduct a gap analysis between their current development plans and the finalized recommendations before advancing to Phase 3 design discussions with the Agency.

Pulmonary TB remains a high-unmet-need indication globally, and FDA's willingness to maintain an active guidance posture in this space reflects ongoing pressure on the antibacterial pipeline. Sponsors operating under Qualified Infectious Disease Product (QIDP) designation or pursuing accelerated approval pathways will find the finalized document particularly relevant to endpoint selection and trial population definitions, areas where draft-to-final changes most commonly occur in antibacterial guidances.

The guidance is issued under 21 CFR 10.115, which governs good guidance practices, and comments remain open on a rolling basis through the docket. Sponsors, CROs, and consultants engaged in TB program design should retrieve the final text directly from FDA's guidance document search and reconcile it against any internal protocol assumptions built on the 2022 draft language.

Regulatory teams have until their next pre-Phase 3 meeting with CDER to align trial designs with the finalized clinical development recommendations outlined in this document.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Guidance Documents RSS Feed, May 8, 2026. Docket: FDA-2013-D-1319.